Celcuity Inc (NASDAQ:CELC) has been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Analysts have set a one year consensus target price of $36.00 for the company and are expecting that the company will post ($0.18) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Celcuity an industry rank of 85 out of 255 based on the ratings given to related companies.
CELC has been the subject of a number of recent analyst reports. Zacks Investment Research downgraded Celcuity from a “strong-buy” rating to a “hold” rating in a report on Wednesday. ValuEngine upgraded Celcuity from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd.
Celcuity (NASDAQ:CELC) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.17) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.03. Analysts predict that Celcuity will post -0.7 earnings per share for the current year.
Institutional investors have recently made changes to their positions in the stock. Gagnon Securities LLC raised its holdings in shares of Celcuity by 0.6% during the second quarter. Gagnon Securities LLC now owns 172,686 shares of the company’s stock valued at $4,317,000 after acquiring an additional 967 shares in the last quarter. Captrust Financial Advisors raised its holdings in shares of Celcuity by 300.0% during the second quarter. Captrust Financial Advisors now owns 3,000 shares of the company’s stock valued at $75,000 after acquiring an additional 2,250 shares in the last quarter. NorthRock Partners LLC bought a new position in shares of Celcuity during the second quarter valued at approximately $323,000. BNP Paribas Arbitrage SA raised its holdings in shares of Celcuity by 13,655.6% during the first quarter. BNP Paribas Arbitrage SA now owns 1,238 shares of the company’s stock valued at $27,000 after acquiring an additional 1,229 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Celcuity by 9.8% during the second quarter. Charles Schwab Investment Management Inc. now owns 14,709 shares of the company’s stock valued at $368,000 after acquiring an additional 1,309 shares in the last quarter. Institutional investors own 22.59% of the company’s stock.
Celcuity Company Profile
Celcuity Inc, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the clinical outcomes of cancer patients treated with targeted therapies in the United States. The company's CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it.
Recommended Story: What is range trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.